Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigms supplementary phase 2B data
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Presentation of phase 2 clinical trial results
- PAR reports successful phase 2 clinical trial
- Paradigm reports consistent oa pain reduction
- Paradigms AGM Presentation
- Paradigm in-licenses treatment for rare joint disease
Later from Paradigm Biopharmaceuticals
- Paradigms orphan phase 2/3 clinical program progresses
- S&P DJI Announces March 2019 Quarterly Rebalance
- Paradigm (PAR) Updated Investor Presentation
- Paradigms secondary endpoints successfully met
- Paradigm launches a$77.9M capital raise
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals